Focal Points with Brom Rector
Elliot Marseille - UC Berkeley Healthcare Economist on the Financial Viability of Psychedelic Therapy
Aug 6, 2023
Dr. Elliot Marseille, UC Berkeley Healthcare Economist, discusses the economic and financial aspects of psychedelic therapies. They explore the cost, insurance coverage, and value of a psychedelic experience. They also highlight the cost-effectiveness of MDMA therapy for PTSD and the potential future availability and affordability of psychedelic therapies.
52:09
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- MDMA-assisted therapy for severe or extreme chronic treatment-resistant PTSD is cost-effective and likely to save healthcare costs.
- Expanding the capacity of clinicians for MDMA-assisted therapy can be achieved through group therapy and technology-assisted therapy.
Deep dives
Cost-effectiveness of MDMA-assisted therapy for PTSD
MDMA-assisted therapy for severe or extreme chronic treatment-resistant PTSD is not only cost-effective but likely to be cost-saving to the healthcare payer.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
